search
Back to results

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

Primary Purpose

Familial Cold Urticaria

Status
Completed
Phase
Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Kineret (anakinra)
Sponsored by
Nova Scotia Health Authority
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Familial Cold Urticaria focused on measuring Familial Cold Urticaria, Kineret (anakinra), Interleukin 1 beta, C-Reactive Protein, Serum Amyloid A protein

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Must be 18 years of age or older at the time of enrollment; may be male or female Must be previously diagnosed with Familial Cold Urticaria (FCU) Must react with at least one of the symptoms of FCU in the summer months at least four times per week sufficiently to interfere with ordinary daily activities or inhibit normal life enjoyment. Women must be willing to have a pregnancy test and if necessary, use contraceptive measures. Exclusion Criteria: Receiving any systemic medications/treatments that could affect FCU. Pregnancy, nursing or planning pregnancy, or, have recently been pregnant to less than three months development and with a history of serious birth defect. Have had any previous treatment with Kineret (anakinra) or any therapeutic agent targeted at IL-1 blockade. Have used any investigational drug within the previous 1 month or five times the half life of the investigational agent, whichever is longer, or 3 months for any biologic of unknown half life. Have received any systemic medication or treatments that could affect the symptoms of FCU such as antihistamines, corticosteroid drugs, NSAIDS, anabolic medications or Ketotifen within 2 weeks of the baseline visit. Have any known malignancy or have a history of malignancy within the previous five years (with the exception of basal or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence).

Sites / Locations

  • Queen Elizabeth Health Sciences Centre

Outcomes

Primary Outcome Measures

To determine the efficacy of kineret (anakinra) 100mg./day in subjects with familial cold urticaria.

Secondary Outcome Measures

To demonstrate the use of C-Reactive Protein (CRP) and Serum Amyloid A Protein (SAA) levels as objective laboratory indicators of effective treatment and to compare the results of two different laboratory methods for the estimation of CRP

Full Information

First Posted
September 21, 2005
Last Updated
November 4, 2022
Sponsor
Nova Scotia Health Authority
Collaborators
Atlantic Provinces Dermatology Association
search

1. Study Identification

Unique Protocol Identification Number
NCT00214851
Brief Title
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Official Title
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Study Type
Interventional

2. Study Status

Record Verification Date
May 2008
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
December 2005 (Actual)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nova Scotia Health Authority
Collaborators
Atlantic Provinces Dermatology Association

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria. Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms triggered by exposure to cold and variable in expression. Currently there is no standard reliable agent available for the treatment of patients with FCU.This study will evaluate the efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and maintenance therapy in patients with FCU.
Detailed Description
Product: Kineret (anakinra) Protocol title: The Use of Kineret (anakinra) in the Treatment of Familial Cold Urticaria (FCU) Target Disease: Familial Cold Urticaria Patients: 8 patients all previously diagnosed with FCU and living close to Moncton, N.B. Study Objectives: To assess the efficacy of Kineret (anakinra) 100mg. given subcutaneously daily in subjects with FCU. To demonstrate the use of CRP and SAA as objective laboratory markers of the effectiveness of treatment. To determine the effect of Kineret (anakinra)on the quality of life of patients with FCU. Study design: An open-labelled trial of Kineret (anakinra) induction therapy (100mg./day) over a four week period. Treatment regimens: After initial clinical and laboratory assessment, the patients will receive Kineret (anakinra) 100mg. daily for four weeks. They will be observed for two further weeks without the medication. Route of administration: Subcutaneous injection Interval between first and last dose of active study agent: 4 weeks Duration of study participation: 8 weeks Number of subjects: 8 Number of sites: 1 Interim analysis: Daily patient diary; weekly follow-up phone calls; CRP reports

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Familial Cold Urticaria
Keywords
Familial Cold Urticaria, Kineret (anakinra), Interleukin 1 beta, C-Reactive Protein, Serum Amyloid A protein

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
8 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Kineret (anakinra)
Intervention Description
Kineret (anakinra 100 mg. s/c daily x 4 weeks
Primary Outcome Measure Information:
Title
To determine the efficacy of kineret (anakinra) 100mg./day in subjects with familial cold urticaria.
Time Frame
Eight weeks
Secondary Outcome Measure Information:
Title
To demonstrate the use of C-Reactive Protein (CRP) and Serum Amyloid A Protein (SAA) levels as objective laboratory indicators of effective treatment and to compare the results of two different laboratory methods for the estimation of CRP
Time Frame
Eight weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Must be 18 years of age or older at the time of enrollment; may be male or female Must be previously diagnosed with Familial Cold Urticaria (FCU) Must react with at least one of the symptoms of FCU in the summer months at least four times per week sufficiently to interfere with ordinary daily activities or inhibit normal life enjoyment. Women must be willing to have a pregnancy test and if necessary, use contraceptive measures. Exclusion Criteria: Receiving any systemic medications/treatments that could affect FCU. Pregnancy, nursing or planning pregnancy, or, have recently been pregnant to less than three months development and with a history of serious birth defect. Have had any previous treatment with Kineret (anakinra) or any therapeutic agent targeted at IL-1 blockade. Have used any investigational drug within the previous 1 month or five times the half life of the investigational agent, whichever is longer, or 3 months for any biologic of unknown half life. Have received any systemic medication or treatments that could affect the symptoms of FCU such as antihistamines, corticosteroid drugs, NSAIDS, anabolic medications or Ketotifen within 2 weeks of the baseline visit. Have any known malignancy or have a history of malignancy within the previous five years (with the exception of basal or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laura A. Finlayson MD FRCPC
Organizational Affiliation
Nova Scotia Health Authority
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queen Elizabeth Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1V7
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

We'll reach out to this number within 24 hrs